Literature DB >> 17515385

Effect of radiofrequency ablation of renal tumors on renal function in patients with a solitary kidney.

Chockeo Syvanthong1, Geoffrey E Wile, Ronald J Zagoria.   

Abstract

OBJECTIVE: The purpose of this study was to evaluate the effect on renal function of percutaneous radiofrequency ablation of renal tumors in patients with a solitary kidney.
CONCLUSION: Ablation resulted in complete tumor eradication, and there were no serious complications. Percutaneous radiofrequency ablation of renal tumors resulted in a 16% increase in serum creatinine concentration and a 13% decrease in creatinine clearance in patients with one kidney. These results are comparable with those of surgical resection of tumors in this group of patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17515385     DOI: 10.2214/AJR.06.0058

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  3 in total

1.  Radiofrequency ablation of renal tumours: diagnostic accuracy of contrast-enhanced ultrasound for early detection of residual tumour.

Authors:  Christine Hoeffel; Maud Pousset; Marc-Olivier Timsit; Caroline Elie; Arnaud Méjean; Samuel Merran; François Tranquart; Ahmed Khairoune; Dominique Joly; Stéphane Richard; Olivier Hélénon; Jean-Michel Correas
Journal:  Eur Radiol       Date:  2010-03-04       Impact factor: 5.315

2.  Percutaneous radiofrequency ablation of small renal tumours in patients with a single functioning kidney: long-term results.

Authors:  Miltiadis Krokidis; Stavros Spiliopoulos; Magdalena Jarzabek; Nikos Fotiadis; Tarun Sabharwal; Tim O'Brien; Andy Adam
Journal:  Eur Radiol       Date:  2013-03-09       Impact factor: 5.315

3.  Radiofrequency Ablation-Assisted Zero-Ischemia Robotic Laparoscopic Partial Nephrectomy: Oncologic and Functional Outcomes in 49 Patients.

Authors:  Kalen Rimar; Aziz Khambati; Barry B McGuire; David A Rebuck; Kent T Perry; Robert B Nadler
Journal:  Adv Urol       Date:  2016-12-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.